СУРУНКАЛИ МИГРЕНЬ. КЛИНИК КУЗАТУВ. ОБЗОР: КЛИНИКА ВА ДАВО
##article.subject##:
Сурункали мигрень, Эпизодик мигрень, Абузус бош оғриқлари, дифференциал диагностика, даволаш усуллари##article.abstract##
Сурункали мигрень (СМ) неврология йўналишини долзарб клиник-ижтимоий муаммолардан бири. Ушбу касалликнинг диагностик критериялари илмий-клиник эволюцияга учради ва замонавий талқин, дифференциал эффектив менежмент ва адекват-патогенетик даво муолажаларига мухтождир. Сурункали мигрень давоси мигренологияни динамик ва тез ривожланувчи соҳаларидан бири. Ушбу йўналишда олиб борилаётган янги изланишлар касалликни диагностикасини енгиллаштириши ва СМ касаллигини шахсий, ижтимоий ва иқтисодий юкламасини енгиллаштириш мақсадида индивидуал даволаш усулларини ишлаб чиқмоқда.
Библиографические ссылки
Артеменко А.Р., Куренков А.Л., Беломестова К.В. Классификация, диагностика и лечение хронической мигрени: обзор новых данных. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;113(11):91–6.
Артеменко А.Р., Куренков А.Л. Хроническая мигрень. М.: АБВ-пресс, 2012. 488 с.
Табеева Г.Р. Головная боль . Руководство дяя врачей. 2018 «Геотар- Медиа», 293 стр.
Сергеев А.В., Мещерина М.И., Табеева Г.Р. Головная боль связанная с избыточным приемом анальгетиков. Эпилепсияипароксизмальноесостояния. 2011, 3, 3, 21-28.
BigalM.E., LiptonR.B. Modifiablerisk factors for migraine progression. Headache 2006;46:1334–43.
Bigal M.E., Ferrari M., Silberstein S.D. et al. Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science. Headache 2009;49:21–33.
Buse D.C., Manack A.N., Fanning K.M. et al. Chronic migraine prevalence, disability, andsociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 2012;52(1):3–17.
Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48:1157–1168.
Blumenfeld A.M., Schim J.D., Chippendale T.J. Botulinum toxin type Aanddivalproex sodium for prophylactic treatment of episodic or chronic migraine.
Headache 2008;48:210–20.
Blumenfeld, S.D. Silberstein, D.W. Dodick, S.K. Aurora, C.C. Turkel, W.J. Binder .Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program Headache, 50 (2010), pp. 1406-1418
Buse DC, Manack AN, Fanning KM et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52:1456–1470.
.Buse DC, Loder EW, Gorman JA et al. Sex differences in prevalence, symptoms, and other features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention Study. Headache.2013;53:1278–1299.
Diener H., Dodick D., Goadsby P. Chronic migraine—classification, characteristics and treatment.Nature Reviews Neurology . 2012. 8, 162–171..
Goadsby P. The diagnosis and treatment of chronic migraine.Ther Adv Chronic Dis.2015 . 6(3): 115–123
Lipton R.B. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache 2011;51:77–83.
Lipton RB, Buse DC, Fanning KM, Serrano D, Reed ML. Suboptimal acute treatment of episodic migraine (EM) is associated with an increased risk of progression to chronic migraine (CM): results of the American Migraine Prevalence and Prevention (AMPP) Study. (LB02) Cephalalgia. 2013;33:954–992.
Lipton R.B., Serrano D., Holland S. et al. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache 2013;53(1):
–92.
Mathew N.T. The prophylactic treatment of chronic daily headache. Headache
;46:1552–64.
Negro A., Rocchietti-March M., Fiorillo M. et al. Chronic migraine: current concepts and ongoing treatments. Eur Rev MedPharmacolSci 2011;15:1401–20.
Olesen J., Goadsby P., Ramadan N. The Headaches. Philadelphia: 2006.
OlesenJ.,Bousser M., First D., et al. New appendix criteria open for a broader concept of chronic migraine. Cephalgia2006 ,26,742-746.
Sher A., Stewart W., Lipton R. Factor associated wich the onset and remission of chronic daily headache in a population-based study. Pain.2003,106,181-189.
Silberstein S., Tfelt-Hansen P., Dodick D.W. et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults.Cephalalgia 2008;28:484–95.
Silberstein SD, Lipton RB, Dodick DW. Operational diagnostic criteria for chronic migraine: expert opinion. Headache. 2014;54:1258–1266.
Silberstein S. Transformd and chrnicmigraine.In : Chronic Dayly Headache. London LBC Decker ,inc. Hamilton,2005,22-56.
Shulte L., May A. Chronic migraine: risk factors, mechanisms and treatment. Nature Reviews Neurology . 2016, 12, 455–464.
